Would you like to contribute to this site?
Arthritis Menu
Submit an Article
Submit a Tip
Place your Ad
Add URL
Arthritis Questions?
Contact Us
Related Topics:
Arthritis Glucosamine Rheumatoid
Arthritis Rheumatism
Cause Rheumatoid Arthritis
Psoriatic Rheumatoid Arthritis
Rheumatoid Arthritis Lung
Rheumatoid Diseases
Rheumatoid Factor
Rheumatoid Factor Test
Rheumatoid Fever
Rheumatoid Lung Disease
Rheumatoid Nodules
Rheumatoid Vasculitis
Symptoms Of Rheumatoid Arthritis
Treating Rheumatoid Arthritis
Other Channels:
|
 |
|
|
|
|
|
|
|
|
Recent Questions and Answers
|
|
|
|
|
|
|
|
Recent Treating Rheumatoid Arthritis News:
|
|
|
Rheumatologic diseases affected over 290,000 children in the U.S. as of 2007, and Juvenile Arthritis is said to be one of the most common childhood diseases in America.
Researchers from across multiple disciplines at NYU Langone Medical Center created a new protein molecule derived from the growth factor progranulin may provide the basis for new therapies in inflammatory diseases, such as rheumatoid arthritis, according to a study published in the March 10, 2011 issue of Science.
Nutra Pharma Recently Interviewed Jeffrey Gottfurcht, Founder of the Jeffrey Gottfurcht Children's Arthritis Foundation, About His Upcoming Mount Everest Expedition and the Physical Challenges He Faces as a Sufferer of Rheumatoid Arthritis
Santarus, Inc. , a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody. The randomized, placebo-controlled, blinded, single-center, single-dose, dose-escalation study is being conducted in Australia in a total of approximately 60 subjects, including healthy volunteers and two cohorts of patients with rheumatoid ...
Lycera Corporation, a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that it has entered into an exclusive research collaboration with Merck to discover, develop and commercialize small molecules that target T-helper 17 (Th17) cells, key mediators of inflammation. The collaboration will focus on ...
|
|
| |
|
|
|
Additional Treating Rheumatoid Arthritis Resources:
|
|
|
|
|
|
|
|
|
Want your site featured on this page?
|
|
 |
|